vimarsana.com

Page 14 - Statistical Methodology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Government Advances in Statistical Programming Workshop 2022 | NSF - National Science Foundation

Parameterising and inferring the effect of a continuous exposure using average derivative effects

Statistical Methods For Comparing Small-Scale Models To At-Scale Biopharmaceutical Manufacturing

Growth Transitions in India : Myth and Reality

Growth has consistently remained a central topic in economic policy considerations of the government in India. However, there has also been a more scholarly interest in it among social scientists. As a part of the latter tradition, this paper addresses the proper delineation of the phases of growth in India, a matter of some discussion in the literature. Using state-of-the-art

Health Canada Approves KEYTRUDA® (pembrolizumab) as First-line Treatment for Adults with Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer

KEYTRUDA ® is an anti-PD-1 therapy that works by helping increase the ability of the body s immune system to help detect and fight tumour cells. 1 An estimated 26,900 Canadians were diagnosed with colorectal cancer in 2020, with an average of 73 Canadians diagnosed daily. 2 KIRKLAND, QC, March 8, 2021 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Health Canada has approved KEYTRUDA ® (pembrolizumab), Merck s anti-PD-1 therapy, for the first-line treatment, as monotherapy, for adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). 3 This approval offers a new first-line treatment option for patients with MSI-H/dMMR metastatic colorectal cancer, said Dr. Ron Burkes, Professor of Medicine, University of Toronto and Medical Oncologist, Mount Sinai Hospital.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.